Implantable Polymer Depot Assembly for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing implantable drug delivery systems lack a true controlled release mechanism, often resulting in a burst release of therapeutic agents upon contact with physiologic fluids, rather than a sustained, controlled release.
Innovation Solution
A depot system comprising a therapeutic region with a bioresorbable polymer and a releasing agent that forms diffusion openings in vivo, allowing for a controlled, sustained release of analgesics over a specified period, typically 7 to 14 days, with a controlled release profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If hydrophilic polymers are added as wetting agents to accelerate drug release, then initial drug release rate is improved, but controlled sustained release is lost
Solution Approach 1:
The polymer carrier is segmented into multiple layers with different compositions and degradation rates. The first layer contains hydrophilic polymers for initial wetting and drug release, while the second layer contains hydrophobic polymers for sustained release. This segmentation allows different regions to perform different functions at different times, resolving the contradiction between rapid initial release and sustained release duration.
Solution Approach 2:
Different regions of the polymer carrier are given different local qualities - the first layer has hydrophilic properties for rapid wetting and drug diffusion, while the second layer has hydrophobic properties for controlled sustained release. This local differentiation allows the system to achieve both rapid initial release and prolonged sustained release without compromise.
2Reliability
If biodegradable polymers are used for localized delivery, then therapeutic efficacy is improved, but burst release occurs
Solution Approach 1:
The polymer carrier is pre-formed with a multi-layer structure before implantation, where the first hydrophilic layer is already in place to facilitate controlled initial release, and the second hydrophobic layer is pre-positioned to prevent burst release. This preliminary structural preparation ensures that when the device is implanted, the drug release follows a controlled profile rather than occurring as an uncontrolled burst.
Solution Approach 2:
The polymer carrier uses a composite structure combining hydrophilic polymers (first layer) and hydrophobic polymers (second layer) in a layered configuration. This composite material approach allows the system to leverage the advantages of both material types - rapid wetting and controlled degradation from the hydrophilic layer, combined with sustained release and burst prevention from the hydrophobic layer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a highly controlled release of therapeutic agents, minimizing initial burst release and ensuring a sustained delivery of analgesics over an extended period, reducing systemic side effects and enhancing treatment efficacy.
Implementation Method 1
the releasing agent is configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region
Implementation Method 2
form diffusion openings in the control region
Implementation Method 3
a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer
Data Source
AI summary
The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.